Arena Investors’s Calidi Biotherapeutics CLDI Stock Holding History

Arena Investors’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-293	Closed	-$349K	–	170
2022 Q2	$349K	Hold	293	–	–	0.15%	81
2022 Q1	$347K	Buy	+293	New	+$346K	0.23%	66

Other funds holding CLDI

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Arena Investors's CLDI Position: Q3 2022 in Review

Arena Investors sold out of Calidi Biotherapeutics (CLDI) in Q3 2022, closing a stake of 293 shares — an estimated $349K sold.

Arena Investors first reported a position in CLDI in Q1 2022 and held it in 2 quarters. The position peaked at $349K in Q2 2022. 21 funds tracked by Wall St. Rank hold CLDI as of Q3 2022.

Arena Investors reported no remaining Calidi Biotherapeutics position as of Q3 2022 after selling out during the quarter.
Arena Investors sold 293 Calidi Biotherapeutics shares in Q3 2022, an estimated $349K.
Arena Investors first reported a position in Calidi Biotherapeutics in Q1 2022 and held it in 2 quarters.
Arena Investors's Calidi Biotherapeutics position peaked at $349K in Q2 2022.
21 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2022.

Based on Arena Investors's 13F filing for Q3 2022, filed 2 Nov 2022.